introduction despite advance imaging technique ability identify diagnose provide easy reliable follow-up many neurosurgical disease particularly high-risk brain tumor stroke condition remains challenging consequently strong impetus promote investigation development novel diagnostic prognostic methodology enhance capability clinician treating patient disease biomarkers emerged increasingly important useful tool complement neuroimaging laboratory explored utility urinary biomarkers management disease study provide proof-of-principle data urinary biomarkers discriminate multiple central nervous system cns disease fig including able distinguish subtypes disease unique tumor pathology stroke condition work described build previously published report tissue-validated longitudinal study urinary biomarkers disorder combination new data presented establish foundation future study predicated leveraging unique cheap non-invasive technique aid clinical care figure disease tree cns central nervous system moyamoya avm arterio-veinous malformation jpa juvenile pilocytic astrocytoma dipg diffuse intrinsic pontine glioma medulloblastoma full size image method patient population given large clinical impact tumor stroke/cerebrovascular disease representative disease group selected study table cerebrovascular condition included moyamoya disease arteriovenous malformation avm tumor condition included three neoplastic lesion including one benign lesion juvenile pilocytic astrocytoma jpa two malignant lesion diffuse intrinsic pontine glioma dipg medulloblastoma disease diagnosis confirmed part routine clinical practice validation imaging review neuroradiology neuropathology confirming tissue diagnosis tumor avms table number average age sex patient selected five cns abnormality included control study full size table sample data collected analyzed institutional review board irb approval boston child hospital method performed accordance relevant guideline regulation furthermore informed consent obtained subject and/or legal guardian total urine sample table analyzed patient different cns anomaly including group patient fatty filum used control study ensure diagnostic panel could differentiate disease also distinct healthy control subject group others previously validated patient control cohort biomarker study given advantageous combination congenital finding coupled individual also neuroimaging exclude pathology might confound analysis urinary biomarker panel panel biomarkers consisted protein known excreted micturition biomarkers matrix metalloproteinases mmp-2 mmp-3 mmp-9 mmp-13 growth factor egf bfgf hb-egf hgf plgf vegf cytokine angiogenin angiopoietin-1 netrin-1 prosaposin thrombospondin-1 thrombospondin-2 cysteine protease cathepsin tissue inhibitor metalloproteinases timp-1 timp-2 timp-3 timp-4 urine collection urine patient 0–25 year age youngest patient month age medulloblastoma juvenile pilocytic astrocytoma moyamoya syndrome arteriovenous malformation diffuse intrinsic pontine glioma along control collected irb approved protocol method performed accordance relevant guideline regulation furthermore informed consent obtained subject and/or legal guardian tumor avm sample confirmed pathologic analysis performed part routine clinical care neuropathologists moyamoya doe result pathology analyzed diagnosis made radiographic clinical criterion urine collected via catheter prior index surgical chemotherapeutic radiotherapeutic intervention disease specimen placed ice collected operating room laboratory personnel upon collection specimen vortexed homogenize content aliquoted microcentrifuge tube stored elisa and/or bead-based multiplexing performed sample quantify level established panel putative urinary biomarkers value normalized total protein concentration using bradford assay value statistically analyzed look biomarkers would distinguish disease control disease protein analysis panel protein selected analysis derived previous work lab others confirming several molecule present selected pathology able detected urine commercially available assay allow validation sample assayed total protein concentration mixing urine solution 2:7 bradford dye bio-rad laboratory inc. distilled water spectral absorbance sample determined using beckman spectrophotometer protein concentration determined using bovine serum albumin bsa standard curve total netrin-1 level determined elisa biomax inc. thrombospondin-1 cathepsin-b level system inc. elisa performed according manufacturer instruction read using filtermax spectrophotometer molecular device level mmp-2 mmp-3 mmp-9 mmp-13 angiogenin angiopoietin pigf thrombospondin-2 vegf egf hgf hb-egf fgfb analyzed using custom luminex® screening assay system inc. timp-1 timp-2 timp-3 timp-4 level analyzed using luminex® performance assay system inc. luminex® assay performed according manufacturer instruction read using bio-plex htf system bio-rad laboratory inc. protein concentration given picograms per microgram pg/μg determined dividing concentration target protein sample pg/ml concentration total protein sample μg/ml normalization measure statistical analysis statistical analysis carried dedicated biostatistician grubb test outlier sensitivity 0.05 applied iteratively data set correct experimental error given much data follow normal distribution nonparametric mann–whitney test used compare level given analyte one disease population level analyte every disease population group control population protein showed significant potential 0.001 differentiating one disease another disease control subjected roc receiver operating characteristic analysis best protein comparison selected based auc area curve roc analysis auc value best biomarkers gathered along value auc protein cutoff level putative diagnostic test using result determined point roc curve sum sensitivity specificity closest statistical analysis performed using prism macintosh graphpad software inc. biomarker study presented accordance reporting recommendation tumor marker prognostic study remark criterion result urinary biomarkers capable distinguishing individual disease cohort applying grubbs test iteratively total extreme value removed total data point 12.29 allowed account variation inherent assay mann–whitney test trimmed data revealed marker capable distinguishing disease disease control table untrimmed heat map presented supplemental data supplemental table includes number additional putative biomarker candidate part initial analysis found significant specie presented table table heat map showing protein different comparing two disease disease control full size table subsequent individual cohort analysis revealed discriminatory biomarkers disease example comparing dipg angiopoietin-1 mmp-13 timp-4 thrombospondin-1 hb-egf found useful differentiating marker timp-4 however showed significant difference expression two population true dipg compared jpa distinguishing marker dipg timp-1 vs. ctrl hb-egf vs. jpa mmp-3 vs. ctrl netrin-1 vs. jpa avm five biomarkers along cutoff point consider biomarker fingerprint dipg using methodology unique fingerprint generated population study comprised specific protein biomarker cutoff level subsequent receiver-operating characteristic roc analysis statistically significant biomarker disease-disease disease-control comparison produced area curve auc sensitivity specificity figure cohort average auc 0.8121 0.0593 average sensitivity specificity 82.15 11.67 77.03 17.66 respectively table biomarker highest auc 0.89 mmp-3 distinguish control patient patient table univariate analysis showing ability urinary biomarkers discriminate two cerebrovascular disease disease control full size table urinary biomarker analysis reveals distinct fingerprint population identified table show every disease-disease disease-control comparison cohort specific protein biomarker significant discriminatory capability fingerprint summated diagnostic map allows immediate comparison disease cut-off point—a heat map putative biomarkers table protein cutoff level determined point roc curve sum sensitivity specificity closest supplemental data show another potential representation highlight specific fingerprint analytes specific cut-off level presented supp fig supp fig represents distribution protein expression control distinct protein expression illustrated supp fig specific fingerprint studied disease purpose attempting characterize disease study speed progression rapidity symptom onset propose rank list sorting condition longest duration disease presentation jpas may take year grow symptomatic lesion versus dipg may take week month cause ischemia day table table illustrating possible diagnostic map clinician full size table urinary biomarker specie correlate biological disparity disease seen table discriminatory biomarkers population varied cohort data reflected difference biological process associated specific disease including tissue remodeling hypoxic response angiogenesis importantly process shared different disease distinct time pathophysiologic progression consequently stratified disease panel time course clinical progression disease ranging indolent progression month year aggressive progression within week month identified biomarkers found significantly different control population disease study figure highlight temporal progression disease subtypes biomarker panel disease rapid temporal progression demonstrate greater number putative biomarkers reflecting dynamic nature multiple related process angiogenesis invasion growth etc requiring elaboration protein seminal several mechanistic pathway time data highlight urinary biomarkers accurately reflect relative biological activity given disease present representative snapshot molecular milieu time sampling figure ranking disease included study according relative indolence aggression measured time course disease table ordering comparison study difference disease difference disease control measured absolute value difference ranking number graph showing statistical difference comparison measured summing statistical significance biomarkers differentiate two condition compared done using standard statistical notation asterisk 0.05 0.01 0.001 0.0001 summing number total asterisk per comparison reflecting amount biological difference indolent aggressive disease full size image discussion background purpose research profound clinical need development better method assist diagnosis prognosis treatment disease particularly central nervous system cns disease cns persist major source morbidity mortality brain tumor leading cause non-trauma/poisoning related death child addition cns remains relatively inaccessible compared organ system direct examination outside expensive imaging invasive sampling lumbar puncture surgical biopsy challenge spurred research novel approach non-invasive biomarkers complement improve upon current clinical practice fig figure reason using urine pediatric brain tumor diagnostic full size image laboratory longstanding interest development non-invasive biomarkers designed aid diagnosis prognosis therapy tumor cerebrovascular disease including biomarker fingerprint distinguish central nervous system tumor moyamoya disease arteriovenous malformation including first report successfully applying novel methodology specifically brain tumor multicenter trial previous study included tissue validation longitudinal study showing change biomarker level time direct correlation change clinical status however despite initial success knowledge gap remains center specificity biomarkers across disease cohort put another way able look detail—with tissue validation longitudinal studies—deeply individual condition compared broadly across different condition thus need ascertain whether urinary biomarkers distinguish different conditions—and ideally also discriminate subtypes within condition discerning different tumor pathology ability provide disease-specific biomarker fingerprint would provide value improving diagnostic accuracy could also serve identify potential therapeutic target consequently project undertaken provide proof-of-principle utility urinary biomarkers particular focus demonstrating ability discriminate specific disease spanning related disparate condition clinical importance rationale use urinary biomarkers important research decision use urine sampling medium ample precedence successful use urinary biomarkers identify physiologic state pregnancy monitor disease diabetes use urinary biomarkers neurological disorder particularly pediatrics offer novel approach provides advantage particularly relevant population current method brain tumor diagnosis follow-up center around use infrequent clinical examination expensive radiographic study computerized tomography magnetic resonance imaging mri often require sedation anesthesia child contrast urine collection carry risk patient far expensive institution urine collection analysis cost approximately 100-times mri easily done shorter interval currently practical imaging study potentially enabling earlier detection recurrent disease dynamic evaluation current response therapy collection urine specimen easy non-invasive avoiding difficulty risk inherent lumbar puncture blood test urine collection done locally mailed saving family travel tertiary care center analysis fast result posted electronically without large complex data set exist imaging test result numerical compared specific statistical cutpoints obviating need analysis relies subjective measure film review tissue staining significantly biomarkers provide method assessment relies metabolic activity different—and complementary—approach current method visual evaluation made imaging study fig figure schematic illustration urinary biomarkers potential non-invasive detection disease full size image urinary biomarker panel selection rationale putative biomarker panel study strategically selected based known excretion urine evidence associated disease investigation availability commercially validated assay molecule detectable urine demonstrated lab others shown play role origin pathology neoplastic vascular disease table worth discussing alternative approach includes indiscriminate screening urinary protein broadly capture potential marker recognize value approach utilize research however given direct clinical focus project sought ensure putative biomarkers commercially available assay important consideration potential use clinical study facilitating rapid external validation group table biomarkers tested current study reported role disease full size table potential application clinical practice study performed provides several key finding relevance clinical practice first far comprehensive disparate array disease included represent largest spectrum cns disorder single study urinary biomarkers date robustly validating efficacy approach better simulating variety condition encountered clinical practice support investigation urinary biomarkers clinical trial done successfully dipg underscoring potential develop disease-specific fingerprint applicability broad range pathophysiological process second data indicate potential creating screening tool leverage specificity identified work general population-based screening relatively rare disease may currently practical work suggests may option develop biomarker panel target specific high-risk population particularly relevant example family risk developing moyamoya current genetic screening looking mutation rnf213 identify at-risk individual distinguish non-affected carrier active disease addition urinary biomarker testing might provide ability reveal at-risk patient may currently active disease offering option cheaper easier perform mri given million individual harbor mutation particularly japanese chinese korean ancestry could great value developing non-invasive tool another example utility illustrated dipg demonstrated previous study—and validated here—the presence dipg detected tracked urinary testing especially important child tumor using mri study tumor burden patient require sedation intubation far riskier brainstem disease affect airway function using urinary biomarkers adjunct tracking disease could potentially reduce frequency mri study saving cost risk population ultimately would anticipate panel biomarkers given disease distinct combination employed based clinical need example one fingerprint might applied screening different group biomarkers might help stratify risk follow response surgery treatment evidenced previous clinical trial data finally role urinary biomarkers may extend beyond diagnostic prognostic adjunct actually inform development novel biologically-based therapy approach combining specific therapy immediate feedback efficacy—theranostics—has rapidly expanded medicine lab started merge field diagnostic biomarkers targeted therapeutic brain cancer tempting consider similar approach cns disorder using biomarker-informed delivery pro-angiogenic therapeutic moyamoya treating tumor targeted chemotherapeutic agent following response therapy using non-invasive urinary biomarkers complement current imaging method limitation future direction data generated research promising limitation inherent work first inherent rarity disease immense clinical impact relatively small cohort limit generalizability conclusion future work build encouraging preliminary data drive multicenter collaboration increase number patient validation second limitation size panel molecule assessed putative biomarkers equipoise benefit expanding number molecule find new candidate biomarkers risk overwhelming volume analysis perform addition molecule robust assay reliable detection remains ongoing challenge currently approaching challenge application high-throughput screening technology continually evolving third question biomarkers may change time whether change levels—if occur—reflect change disease status data select condition moyamoya avms brain tumor indicating biomarkers accurately track response therapy validation across larger population condition important clear advocating methodology would replace current practice imaging study biopsy needed rather hope approach would serve complement modality increasing accuracy decreasing cost—ideally benefit patient clinician alike conclusion report novel panel urinary biomarkers distinguish range common clinically relevant cns disease high sensitivity specificity data demonstrate proof-of-principle evidence disease-specific urinary biomarker signature exist work potential enhance diagnostic prognostic therapeutic capability clinician though use disease-specific biomarker panel assessed non-invasively offering unique advantage safety ease monitoring reduced cost along new quantifiable biological approach complement existing clinical radiographic practice